Prescribe targeted oncology therapeutics considering panels of resistance genetic variants
Drugs are designed to bind to specific protein targets. Common genetic variation affects the drug binding site and action of the protein and can affect the efficacy of a drug, but this is generally not considered in the preclinical testing prior to a clinical trial. For the most popular precision oncology therapeutics, some resistance mutations are later identified and considered when prescribing a companion diagnostic test. However, there is no systematic approach to identify drug resistance. If this information were available to oncologists, it could be used to select among different drugs for more effective data-driven treatment.
Genetic variation can produce drug resistance
Little is known about drug resistance for precision oncology
MEGA-Maps™ with and without drugs can identify all resistance mutations in a target for a drug
Enables precision prescriptions
Making drugs more effective
Our custom genetic drug resistance panels are the future of better targeted therapies
Powering precision prescriptions because patients and payers want drugs that work
Identify 100s of target-derived resistance mutations and their causative effects in just months instead of years.